Edition:
United States

Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

1.51USD
22 Jun 2018
Change (% chg)

$0.01 (+0.67%)
Prev Close
$1.50
Open
$1.50
Day's High
$1.57
Day's Low
$1.50
Volume
16,199
Avg. Vol
18,254
52-wk High
$4.40
52-wk Low
$1.29

Latest Key Developments (Source: Significant Developments)

Cyclacel Pharmaceuticals Reports Q1 Loss Per Share $0.12
Monday, 14 May 2018 04:05pm EDT 

May 14 (Reuters) - Cyclacel Pharmaceuticals Inc ::CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.CYCLACEL PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.12.  Full Article

Cyclacel Pharmaceuticals Posts Qtrly Loss Of $2.1 Mln
Wednesday, 28 Mar 2018 04:05pm EDT 

March 28 (Reuters) - Cyclacel Pharmaceuticals Inc ::CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.CYCLACEL PHARMACEUTICALS - ‍AS OF DEC 31, 2017, CASH AND CASH EQUIVALENTS TOTALED $23.9 MILLION, COMPARED TO $16.5 MILLION LAST YEAR.CYCLACEL PHARMACEUTICALS INC - NET LOSS APPLICABLE TO COMMON SHAREHOLDERS FOR THREE MONTHS ENDED DEC 31, 2017 WAS $2.1 MILLION​.  Full Article

Cyclacel Pharma Projects Cash Resources To Fund Currently Planned Programs Through End Of 2019
Tuesday, 9 Jan 2018 07:00am EST 

Jan 9 (Reuters) - Cyclacel Pharmaceuticals Inc ::CYCLACEL PHARMACEUTICALS INC - CO PROJECTS CASH RESOURCES TO FUND CURRENTLY PLANNED PROGRAMS THROUGH END OF 2019.  Full Article

Cyclacel Pharmaceuticals Q3 loss per share $0.91 including items
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Cyclacel Pharmaceuticals Inc ::Cyclacel Pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.91 including items.  Full Article

Cyclacel Pharmaceuticals Q2 loss per share $0.50
Wednesday, 9 Aug 2017 04:05pm EDT 

Aug 9 (Reuters) - Cyclacel Pharmaceuticals Inc :Cyclacel Pharmaceuticals reports second quarter 2017 financial results.Q2 loss per share $0.50.  Full Article

Cyclacel Pharma files for potential offering of up to $15 mln
Friday, 26 May 2017 05:18pm EDT 

May 26 (Reuters) - Cyclacel Pharmaceuticals Inc :Cyclacel pharmaceuticals inc- files for potential offering of up to $15 million - sec filing.  Full Article

Cyclacel Pharmaceuticals Q1 loss per share $0.38
Thursday, 11 May 2017 04:05pm EDT 

May 11 (Reuters) - Cyclacel Pharmaceuticals Inc ::Cyclacel pharmaceuticals reports first quarter 2017 financial results.Q1 loss per share $0.38.  Full Article

Cyclacel Pharmaceuticals reports Q4 and full year 2016 financial results
Tuesday, 28 Mar 2017 04:05pm EDT 

Cyclacel Pharmaceuticals Inc - : Cyclacel Pharmaceuticals reports fourth quarter and full year 2016 financial results . Says net loss for three months and year ended December 31, 2016 was $2.8 million and $11.8 million respectively .Says revenue for three months and year ended December 31, 2016 were $0.3 million and $0.8 million respectively.  Full Article

Cyclacel reports top-line results from phase 3 study in patients with acute myeloid leukemia
Thursday, 23 Feb 2017 06:57am EST 

Cyclacel Pharmaceuticals Inc : Cyclacel announces top-line results from pivotal phase 3 seamless study in elderly patients with acute myeloid leukemia . Cyclacel Pharmaceuticals Inc - study did not reach statistically significant improvement in primary endpoint of overall survival . Cyclacel Pharmaceuticals Inc - improvement in secondary endpoint of complete remission rate for experimental arm . Cyclacel Pharmaceuticals Inc says cash resources are projected to fund these activities and operations through end of 2018 . Cyclacel Pharmaceuticals Inc - cash resources are projected to fund these activities and operations through end of 2018 .Cyclacel Pharmaceuticals-plan to discuss data from seamless with european, us regulators once subgroup analyses are completed in next few months.  Full Article

Tang Capital Partners Lp says 9.6 pct stake in Cyclacel Pharmaceuticals
Friday, 19 Aug 2016 05:54pm EDT 

Tang Capital Partners Lp:Tang Capital Partners Lp reports 9.6 pct passive stake in Cyclacel Pharmaceuticals Inc as of Aug 12 - SEC Filing.  Full Article